Heerka dhacdooyinka kansarka qanjirka 'prostate' ayaa sii kordhaya sanadba sanadka ka dambeeya, wuxuuna noqday mid ka mid ah dilaaga waaweyn ee saameeya caafimaadka ragga da'da ah.Waqtigan xaadirka ah, Shiinuhu wuxuu dejiyay heerar baaris oo cad oo kansarka qanjirka 'prostate' ah, laakiin wali waxay u baahan tahay inay sii wado kor u qaadista caannimada wacyigelinta baarista dadweynaha.Ye Dingwei, oo ah gudoomiye ku xigeenka Cisbitaalka Kansarka ee xidhiidhka la leh Jaamacadda Fudan ahna madaxa qaybta kaadi mareenka, ayaa ka sheegay shirkii ugu dambeeyay ee khubarada cilmi-baadhista ee khubarada horumarinta kansarka qanjirka ‘prostate’ oo lagu qabtay Guangzhou in Shiinuhu wali u baahan yahay in uu xoojiyo doorkiisa hoggaamineed ee cilmi-baadhista dawooyinka hal-abuurka leh ee caalamiga ah iyo horumarinta tijaabooyinka bukaan-socodka, si loo dardargeliyo ballaarinta iyo soo bandhigida dawooyin cusub oo badan oo ay ka faa'iidaystaan bukaanno badan oo Shiinaha ah.
Kansarka qanjirka 'prostate' waa buro malignant epithelial ah oo ku dhacda qanjirka 'prostate' waana tan ugu badan ee ku dhacda habka kaadiheysta ee ragga.Sababtoo ah ma laha calaamado caafimaad oo gaar ah marxaladda hore, inta badan waxay ku qaldaan dhakhaatiirta ama bukaannada qanjirka 'prostate hypertrophy' ama hyperplasia, iyo xitaa bukaanno badan uma yimaadaan inay arkaan takhtar ilaa ay yeeshaan calaamado metastatic ah sida xanuunka lafaha.Natiijo ahaan, ku dhawaad 70% bukaannada kansarka qanjirka 'prostate' ee Shiinaha waa kuwo maxalli ah oo horumaray iyo kansarka qanjirka 'prostate' oo ballaaran mar la ogaado, oo leh daaweyn xumo iyo saadaalin.Waxaa intaa dheer, heerka dhacdooyinka kansarka qanjirka 'prostate' waxay kordhisaa da'da, kor u kaca si xawli ah ka dib da'da 50, iyo heerka dhacdooyinka iyo heerka dhimashada ee 85 sano ayaa gaaray meeshii ugu sareysay.Marka la eego asalka gabowga qoto dheer ee Shiinaha, tirada guud ee dadka qaba kansarka qanjirka 'prostate' ee Shiinaha ayaa kor u kici doona.
Ye Dingwei ayaa sheegay in kororka heerka dhacdooyinka kansarka qanjirka 'prostate' ee Shiinaha uu ka sarre maray burooyinka kale ee adag, heerka dhimashaduna sidoo kale aad ayuu kor ugu kacayaa.Isla markaana, heerka badbaadada kansarka qanjirka 'prostate' ee Shiinaha ee shanta sano ayaa ka yar 70%, halka Yurub iyo Mareykanka, gaar ahaan Mareykanka, heerka badbaadada shanta sano uu ku dhow yahay 100%."Sababta ugu weyn ee xaaladdan ayaa ah in wacyiga baaritaanka guud ee Shiinaha uu weli daciif yahay, mana jirto wax la isku raacsan yahay oo ku saabsan wacyiga in kooxaha khatarta sare leh ay maraan baaritaanka PSA labadii sanaba mar;Bukaanjiifka qaarna ma helin ogaanshaha iyo daawaynta caadiga ah, iyo dhammaan nidaamka maaraynta habka maaraynta kansarka qanjirka 'prostate' ee Shiinaha ayaa weli u baahan in la hagaajiyo."
Sida kansarrada intooda badan, ogaanshaha hore, ogaanshaha iyo daawaynta kansarka qanjirka 'prostate' waxay kordhin kartaa heerka badbaadada.Zeng Hao, oo xubin ka ah Kooxda Cilmi-baarista Dhallinyarada, ahna Xoghayaha Guud ee Laanta Urology ee Ururka Dhakhaatiirta Shiinaha, ayaa sheegay in dadka reer Yurub iyo Maraykanku ay muhiimad weyn siiyaan ka hortagga iyo daaweynta kansarka qanjirka 'prostate', heerka baaritaanka kansarka qanjirka 'prostate' ayaa ah mid yar. sare, kaas oo u oggolaanaya bukaanno badan oo qaba kansarka qanjirka 'prostate' si ay u helaan fursado daweyn oo wanaagsan, halka dadweynaha Shiinaha ay leeyihiin wacyigelin hoose oo ku saabsan baarista cudurrada, iyo badi bukaannada ayaa ah kuwo gudaha ah oo horumaray iyo kansarka qanjirka 'prostate' marka la ogaado.
"Weli waxaa jira farqi weyn oo u dhexeeya bukaannada kansarka qanjirka 'prostate' ee Shiinaha iyo Yurub iyo Mareykanka laga bilaabo bilawga cudurka ilaa daaweynta iyo saadaasha.Sidaa darteed, ka-hortagga iyo daawaynta kansarka qanjirka 'prostate' ee Shiinaha waxay leedahay waddo dheer oo loo maro," ayuu yiri Zeng Hao.
Sidee loo badalaa xaalada taagan?Ye Dingwei ayaa sheegay in tan koowaad ay tahay in la faafiyo wacyiga baaritaanka hore.Bukaanka qanjirka 'prostate' ee ka weyn 50 sano ee khatarta sare leh waa in laga baaro prostate-ka gaarka ah (PSA) labadii sanaba mar.Marka labaad, daaweynta kansarka qanjirka 'prostate' waa in ay fiiro gaar ah u leedahay daaweynta saxda ah iyo fikradda geedi socodka oo dhan.Saddexaad, daawaynta, waa in aan fiiro gaar ah u yeelano daawaynta kala-duwanaanshaha (MDT) ee bukaanada qaba kansarka qanjirka 'prostate' ee marxaladaha dhexe iyo dambe.Dadaalka wadajirka ah ee hababka badan ee kor ku xusan, heerka guud ee badbaadada kansarka qanjirka 'prostate' ee Shiinaha ayaa laga yaabaa in si weyn loo hagaajiyo mustaqbalka.
"Weli waxaan haynaa waddo dheer oo aan ku hagaajin karno heerka ogaanshaha hore iyo heerka saxda ah ee ogaanshaha."Zeng Hao wuxuu sheegay in dhibka ugu weyn ee lagu hagaajinayo ogaanshaha hore iyo heerka daawaynta hore ay tahay in waxqabadka kiliinikada, qiimaha calaamadaha buradu ay tahay kaliya tilmaame tixraaceed oo muhiim ah, iyo ogaanshaha buro waxay u baahan tahay in lagu daro sawir-qaadis ama daloolin ka-qaadis si loo dhammaystiro. ogaanshaha, laakiin da'da dhexdhexaadka ah ee bukaanka kansarka qanjirka 'prostate' waa inta u dhaxaysa 67 iyo 70 sano jir ah, Noocan ah bukaanada waayeelka ah ayaa hoos u dhac ku ah aqbalida ka-qaadista daloolin.
Waqtigan xaadirka ah, hababka daaweynta caadiga ah ee kansarka qanjirka 'prostate' waxaa ka mid ah qaliinka, daaweynta shucaaca, kiimoterabiga iyo daaweynta endocrine, kuwaas oo daaweynta endocrine ay tahay habka ugu weyn ee daaweynta kansarka qanjirka 'prostate'.
Ye Dingwei ayaa sheegay in natiijooyinka ASCO-GU ee hadda la sii daayay sanadkan ay muujiyeen in daaweynta isku dhafan ee ka kooban PARP inhibitor Talazoparib iyo enzalutamide ay ku guuleysteen natiijooyin wanaagsan oo ku saabsan tijaabada wajiga III ee bukaan-socodka, iyo guud ahaan muddada badbaadada ayaa sidoo kale si weyn loo hagaajiyay, iyadoo Natiijooyin aad u wanaagsan oo la filayo, rajada laga qabo in la hagaajiyo tayada guud ee nolosha bukaanka qaba kansarka qanjirka 'prostate' mustaqbalka.
"Weli waxaa jira daloolo xagga suuqa ah iyo baahiyaha daawaynta ee aan la daboolin marka la soo bandhigo dawooyinka cusub ee dalkeena."Ye Dingwei waxa uu sheegay in uu rajaynayo in uu dardargeliyo soo saarista dawooyinka hal-abuurka leh, waxa kale oo uu rajaynaya in kooxda caafimaadka ee Shiinuhu ay ka qayb-qaadan karaan tijaabooyinka caafimaad ee dawooyinka caalamiga ah, isla markaana ay la mid yihiin cilmi-baadhisyada iyo horumarinta iyo suuqgeynta shisheeye, isla markaana ay ka wada shaqeeyaan sidii ay wax badan u keeni lahaayeen. Ikhtiyaarada daawaynta cusub ee bukaanka, wanaajiya heerka ogaanshaha hore iyo guud ahaan badbaadada.
JinDun Medicalwaxay leedahay iskaashi cilmi-baaris cilmiyeed oo muddo-dheer ah iyo ku-tallaalidda tignoolajiyada jaamacadaha Shiinaha.Iyada oo Jiangsu kheyraad caafimaad qani ah, waxay leedahay xiriir ganacsi oo muddo dheer India, Koonfur-bari Asia, South Korea, Japan iyo suuqyada kale.Waxa kale oo ay bixisaa adeegyada suuqa iyo iibka ee geeddi-socodka oo dhan laga bilaabo dhexe ilaa API alaabta dhammaatay.Ka faa'iidayso agabka la ururiyey ee Kiimikada Yangshi ee kimistariga fluorine si aad u bixiso adeegyo gaar ah oo kiimikaad ah oo loogu talagalay lammaanayaasha.Bixi habka hal-abuurka iyo adeegyada cilmi-baarista wasakhaysan si loo beegsado macaamiisha.
JinDun Medical wuxuu ku adkaysanayaa in la abuuro koox leh riyooyin, samaynta alaabooyin leh sharaf, taxadar leh, adag, oo dhan u baxa si ay u noqdaan lammaane la aamini karo iyo saaxiibka macaamiisha! xirfadlewax-soo-saarka dawooyinka la habeeyey(CMO) iyo R&D dawada la habeeyey iyo adeeg bixiyayaasha wax soo saarka (CDMO).
Waqtiga boostada: Mar-20-2023